The company reported mixed third-quarter results for 2025, with core EPS up 7% year-over-year while free cash flow remained negative, largely driven by seasonal factors and ongoing regulatory challenges.
- Crop Science showed resilience with corn sales up 9% year-to-date, despite Q3 being typically weaker for the agriculture sector.
- Pharmaceuticals delivered strong performance, particularly with Nubeqa and Kerendia, which saw year-over-year growth of 60% and 80%, respectively.
- Consumer Health is facing a challenging market environment, prompting a downward revision of full-year sales expectations.
- Management remains confident in achieving 2025 guidance amid ongoing litigation challenges and regulatory pressures.
- The FDA approval of Lynkuet and positive data from the Kerendia study present growth opportunities beyond 2025.
Community Discussion